Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 11;10(11):e0142425.
doi: 10.1371/journal.pone.0142425. eCollection 2015.

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study

Helen R Stagg  1 , James Brown  2   3 , Elmira Ibraim  4 , Vija Riekstiņa  5   6 , Piret Viiklepp  7 , Andra Cīrule  5 , Horia Cocei  4 , Manfred Danilovitš  8 , Gunta Dravniece  9 , Charlotte Jackson  1 , Peter J White  10   11
Affiliations

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study

Helen R Stagg et al. PLoS One. .

Abstract

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant tuberculosis cases, highlight the difficulties in designing universal regimen, and inform future regimen selection. Demographic and microbiological surveillance data for multidrug resistant tuberculosis cases from 2004-13 were analysed. High levels of additional resistance to currently recommended second line drugs were seen in all settings, with extensive variability between countries. Accurate drug susceptibility testing and drug susceptibility testing data are vital to inform the development of comprehensive, flexible, multidrug resistant tuberculosis guidance.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors of this manuscript have read the journal's policy and have the following competing interests: Dr. Stagg reports personal fees and other from Otsuka Pharmaceutical, grants from National Institute for Health Research, UK, during the conduct of the study; non-financial support from Sanofi, outside the submitted work. Dr. Brown reports grants and personal fees from Otsuka Pharmaceuticals, during the conduct of the study. Dr. White reports grants and personal fees from Otsuka, during the conduct of the study. Dr. Danilovits reports personal fees and other from Otsuka Pharmaceutical, during the conduct of the study. Dr. Viiklepp reports grants from UCL Consultants Ltd, during the conduct of the study. Dr. Ibraim reports personal fees and non-financial support from Otsuka SA, during the conduct of the study; grants from German Centre for Infection Research- DZIF, outside the submitted work. Dr. Dravniece reports grants and personal fees from Otsuka, during the conduct of the study. Dr. Cocei reports grants from Otsuka SA, during the conduct of the study; grants from Romanian National Tuberculosis Programme, grants from Norway Grants, outside the submitted work. Dr. Jackson reports personal fees from Otsuka Pharmaceutical, grants from National Institute for Health Research, during the conduct of the study. Dr. Riekstina reports personal fees from Otsuka Pharmaceutical (Switzerland) during the conduct of the study. Dr. Cirule has nothing to disclose. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

References

    1. World Health Organization. Global tuberculosis report 2014 World Health Organization; 2014. [cited 2014 Nov 28]; Available: http://www.who.int/tb/publications/global_report/en/
    1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update World Health Organization; 2011. [cited 2014 Nov 27]; Available: http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf?ua=1 - PubMed
    1. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013. May;12(5):388–404. 10.1038/nrd4001 - DOI - PubMed
    1. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs World Health Organization; 2008. [cited 2015 Oct 1]; Available: http://www.who.int/tb/publications/2008/who_htm_tb_2008_392.pdf - PubMed
    1. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2010. January;48(1):300–1. 10.1128/JCM.01775-09 - DOI - PMC - PubMed

Publication types

MeSH terms